Statement Regarding Industry Funding
Approved by Board of Trustees May 2020
Sabin partners with multiple organizations in the vaccine and immunization community, including the pharmaceutical and biotechnology industry (industry), to implement its Global Immunization and Research & Development Programs. Sabin operates independently from industry and controls and restricts programs and activities that may be supported by industry as outlined below. Furthermore, this policy is reviewed annually by Sabin's Board of Trustees.
Global Immunization Programs. Industry has no role in Sabin’s Global Immunization program design, development or outputs, including findings and analysis. It is Sabin's policy that less than 15% or $2.5M of a three-year rolling average of Global Immunization program funding is received from industry.
Research & Development Programs. To complement its in-house R&D team, Sabin leverages the expertise of partners in government, academia, non-profit institutions and industry, including contract research/manufacturing organization. Operating through negotiated agreements (such as Research Services, Material Transfer, Research & License and Clinical Trial Agreements), Sabin selects partners based on expertise, track record, price, project/funder requirements, and other competitive and due diligence processes. Depending on the partnership structure, Sabin may provide or receive funding from industry to support specific vaccine development activities.